Quick Answer
Aprea Therapeutics, Inc. reported Stockholders Equity of $12.44 million for the year ending 2025.
- Aprea Therapeutics, Inc. showed a decrease of -35.6% in Stockholders Equity from 2024 to 2025.
- This data is from Aprea Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$44.48 million | Q3 2018: -$47.47 million | Q1 2019: -$56.82 million | Q2 2019: -$61.85 million | Q3 2019: -$70.80 million | Q1 2020: $113.35 million | Q2 2020: $100.12 million | Q3 2020: $89.02 million | Q1 2021: $69.15 million | Q2 2021: $60.95 million | Q3 2021: $53.42 million | Q1 2022: $43.59 million | Q2 2022: -$35.78 million | Q3 2022: $26.63 million | Q1 2023: $26.48 million | Q2 2023: $23.42 million | Q3 2023: $20.29 million | Q1 2024: $28.92 million | Q2 2024: $25.56 million | Q3 2024: $21.95 million | Q1 2025: $15.55 million | Q2 2025: $13.41 million | Q3 2025: $10.91 million.
- Over the full 10 years of available data (2016 to 2025), Aprea Therapeutics, Inc.'s Stockholders Equity has grown by 158.0%.
- Historical annual values: Fiscal year 2025: $12.44 million | Fiscal year 2024: $19.31 million | Fiscal year 2023: $16.95 million | Fiscal year 2022: $25.64 million | Fiscal year 2021: $49.51 million | Fiscal year 2020: $77.40 million | Fiscal year 2019: $124.24 million | Fiscal year 2018: -$51.44 million | Fiscal year 2017: -$35.77 million | Fiscal year 2016: -$21.47 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: